What is SpyGlass Pharma, Inc.'s (SGP) StockRank?

MoatMap's StockRank for SpyGlass Pharma, Inc. (SGP) is 14/100, with a Strong Sell signal. This is a composite score combining Quality (38), Value (41), and Momentum (22) factor ranks across MoatMap's 20,000+ stock universe.

Does SpyGlass Pharma, Inc. have an economic moat?

SpyGlass Pharma, Inc. (SGP) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is SpyGlass Pharma, Inc. a buy, hold, or sell?

MoatMap's current signal for SpyGlass Pharma, Inc. (SGP) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is SpyGlass Pharma, Inc. in?

SpyGlass Pharma, Inc. (SGP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SGP

STRONG SELLREMOVE

SpyGlass Pharma, Inc. · Healthcare · United States · $663M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-67.7%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

SpyGlass Pharma is a private/early-stage venture-backed ophthalmic drug delivery company. It lacks established commercial revenues, owner earnings, and a proven business model, making it unsuitable for our concentrated public equity strategy.

COMPANY DESCRIPTION

SpyGlass Pharma, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on developing a proprietary sustained-release drug delivery platform for the treatment of glaucoma. Its innovative implantable technology aims to provide long-term, continuous medication delivery, addressing patient adherence challenges and potentially improving therapeutic outcomes. The company is poised to disrupt the glaucoma treatment market with its novel drug-device combination.

FINANCIAL SUMMARY (USD)

Year	2023	2024
Revenue	0	0
EPS	-0.24	-0.45
Shares	—	—
Debt	0	4M
Equity	-33M	-60M
Op CF	-12M	-22M
Inv CF	-20M	22M
Fin CF	40M	184,990

PRICE (1M)-26.3%

SMA 50SMA 200

$18.70

RSI (14)

46.0

SCORE BREAKDOWN

Quality

ROIC

-38.6%17.8

ROE

-67.7%12.8

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-19.2%17.6

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.01x85.4

Current Ratio

12.67x90.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-17.5x86.0

P/FCF

—N/A

P/B

2.5x47.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-101%4.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$663M

P/E (Forward)

-6.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGP are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SGP	SpyGlass Pharma, Inc.(you)	$663M	14	STRONG SELL
0IL8.L	Kyntra Bio, Inc.	$666M	14	STRONG SELL
BBOT	BridgeBio Oncology Therapeutics, Inc.	$708M	12	STRONG SELL
ARVN	Arvinas, Inc.	$570M	14	STRONG SELL
EIKN	Eikon Therapeutics, Inc.	$558M	13	STRONG SELL
PROK	ProKidney Corp.	$547M	11	STRONG SELL
DRUG	Bright Minds Biosciences Inc.	$878M	15	STRONG SELL
TRAX	First Tracks Biotherapeutics, Inc.	$552M	10	STRONG SELL
EDIT	Editas Medicine, Inc.	$526M	10	STRONG SELL
CTMX	CytomX Therapeutics, Inc.	$808M	18	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

SpyGlass Pharma, Inc. (SGP) — Stock Score Summary

SpyGlass Pharma, Inc. (SGP) has a MoatMap StockRank of 14/100 based on Quality (38/100), Value (41/100), and Momentum (22/100) factor scores. The current signal is STRONG SELL. SpyGlass Pharma is a private/early-stage venture-backed ophthalmic drug delivery company. It lacks established commercial revenues, owner earnings, and a proven business model, making it unsuitable for our concentrated public equity strategy.

Key Financial Metrics

Price	$18.70
Market Cap	$663M
P/E (Forward)	-6.84
Price/Book	2.46
Return on Equity	-67.7%
Return on Invested Capital	-38.6%
Debt/Equity	1.50
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-22M

SpyGlass Pharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is SpyGlass Pharma, Inc.’s (SGP) StockRank?: MoatMap’s StockRank for SpyGlass Pharma, Inc. (SGP) is 14/100, with a Strong Sell signal. It is a composite of Quality (38), Value (41), and Momentum (22) factor ranks across MoatMap’s 20,000+ stock universe.
Does SpyGlass Pharma, Inc. have an economic moat?: SpyGlass Pharma, Inc. (SGP) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is SpyGlass Pharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for SpyGlass Pharma, Inc. (SGP) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is SpyGlass Pharma, Inc. in?: SpyGlass Pharma, Inc. (SGP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).